CL2019003813A1 - Polipéptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y métodos de uso. - Google Patents

Polipéptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y métodos de uso.

Info

Publication number
CL2019003813A1
CL2019003813A1 CL2019003813A CL2019003813A CL2019003813A1 CL 2019003813 A1 CL2019003813 A1 CL 2019003813A1 CL 2019003813 A CL2019003813 A CL 2019003813A CL 2019003813 A CL2019003813 A CL 2019003813A CL 2019003813 A1 CL2019003813 A1 CL 2019003813A1
Authority
CL
Chile
Prior art keywords
retinopathyal
amd
retinopathy
diseases
polypeptides
Prior art date
Application number
CL2019003813A
Other languages
English (en)
Spanish (es)
Inventor
Edwin L Madison
Vanessa Soros
Mikhail Popkov
Original Assignee
Catalyst Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalyst Biosciences Inc filed Critical Catalyst Biosciences Inc
Publication of CL2019003813A1 publication Critical patent/CL2019003813A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21109—Matriptase (3.4.21.109)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Photolithography (AREA)
  • Beans For Foods Or Fodder (AREA)
CL2019003813A 2017-06-22 2019-12-23 Polipéptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y métodos de uso. CL2019003813A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762523735P 2017-06-22 2017-06-22
US201862664051P 2018-04-27 2018-04-27

Publications (1)

Publication Number Publication Date
CL2019003813A1 true CL2019003813A1 (es) 2020-05-29

Family

ID=63015005

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2019003813A CL2019003813A1 (es) 2017-06-22 2019-12-23 Polipéptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y métodos de uso.
CL2021003080A CL2021003080A1 (es) 2017-06-22 2021-11-22 Polipéptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y métodos de uso (divisional de la solicitud no. 201903813)
CL2021003081A CL2021003081A1 (es) 2017-06-22 2021-11-22 Polipéptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y métodos de uso (divisional de la solicitud no. 201903813)

Family Applications After (2)

Application Number Title Priority Date Filing Date
CL2021003080A CL2021003080A1 (es) 2017-06-22 2021-11-22 Polipéptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y métodos de uso (divisional de la solicitud no. 201903813)
CL2021003081A CL2021003081A1 (es) 2017-06-22 2021-11-22 Polipéptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y métodos de uso (divisional de la solicitud no. 201903813)

Country Status (19)

Country Link
US (5) US10781435B2 (https=)
EP (1) EP3641801A1 (https=)
JP (3) JP7091373B2 (https=)
KR (1) KR102675270B1 (https=)
CN (1) CN111107870A (https=)
AU (2) AU2018290281B2 (https=)
BR (1) BR112019027583A2 (https=)
CA (2) CA3177086A1 (https=)
CL (3) CL2019003813A1 (https=)
CO (1) CO2020000584A2 (https=)
IL (2) IL308949B2 (https=)
JO (1) JOP20190288A1 (https=)
MX (1) MX2019015402A (https=)
MY (1) MY202652A (https=)
PE (1) PE20200697A1 (https=)
PH (1) PH12019502838A1 (https=)
SG (3) SG11201912071QA (https=)
WO (1) WO2018237201A1 (https=)
ZA (1) ZA202000332B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
CA3177086A1 (en) * 2017-06-22 2018-12-27 Catalyst Biosciences, Inc. Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use
KR102439221B1 (ko) 2017-12-14 2022-09-01 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
CN114269937B (zh) * 2019-07-03 2026-04-24 帕利昂制药有限公司 重组唾液酸酶及其使用方法
US11396529B2 (en) * 2020-11-12 2022-07-26 National Sun Yat-Sen University Isolated peptide, anti-cancer medicinal composition including the same and method of specifically reducing or inhibiting activities of cancer cells using the same
KR20230142496A (ko) * 2021-01-08 2023-10-11 버텍스 파마슈티칼스 인코포레이티드 인자 b 프로테아제
CN113456527B (zh) * 2021-07-30 2023-04-07 北京清大赛尔生物科技有限公司 一种nadh微胶囊制剂及其制备方法和应用
WO2024205149A1 (ko) * 2023-03-24 2024-10-03 카오티에스 주식회사 신규한 그랜자임 융합단백질 및 이의 용도
CN119570766B (zh) * 2025-02-08 2025-05-16 上海锴泰生物科技有限公司 一种胶原蛋白酶突变体、基因片段、重组质粒、重组表达体系、胶原蛋白肽，及其制备方法和用途
CN121538228B (zh) * 2026-01-21 2026-04-10 山东寿光巨能金玉米开发有限公司 一种NCgl0081基因突变体及其在制备L-赖氨酸中的应用

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US237A (en) 1837-06-15 Egbert beale
US5324A (en) 1847-10-09 Cooking-stove
US5795A (en) 1848-09-19 Saddletree for carts
US569A (en) 1838-01-09 Caruiag-e-spiiln g
US844A (en) 1838-07-17 Boiler for
US5990A (en) 1848-12-26 of baltimore
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
DE3921528A1 (de) 1989-06-30 1991-01-10 Draegerwerk Ag Messzelle fuer den elektrochemischen gasnachweis
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
WO1994028024A1 (en) 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
GEP20002180B (en) 1994-03-31 2000-07-25 Amgen Inc Composition and Methods for Stimulating Megakaryocyte Growth and Differentiation
US5795569A (en) 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6258351B1 (en) 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
JP4078032B2 (ja) 1998-03-12 2008-04-23 ネクター セラピューティックス エイエル，コーポレイション 近位の反応性基を持つポリ（エチレングリコール）誘導体
CN1314992A (zh) 1998-07-03 2001-09-26 奈勒斯菲尔德控制有限公司 流体测量的方法和装置
US6153394A (en) 1998-09-18 2000-11-28 Board Of Trustees Operating Michigan State University Immunoassay for equine protozoal myeloencephalitis in horses
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
AU7497000A (en) 1999-02-28 2000-11-14 Washington University Novel transduction molecules and methods for using same
EP1161266A4 (en) 1999-03-12 2007-09-19 Univ Georgetown Matriptase, a serine protease and its applications
JO2291B1 (en) 1999-07-02 2005-09-12 اف . هوفمان لاروش ايه جي Erythropoietin derivatives
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US6461802B1 (en) 1999-08-02 2002-10-08 Agfa-Gevaert Adhesive layer for polyester film
US7030231B1 (en) 1999-09-30 2006-04-18 Catalyst Biosciences, Inc. Membrane type serine protease 1 (MT-SP1) and uses thereof
WO2001032711A2 (en) 1999-10-21 2001-05-10 Board Of Trustees Of The University Of Arkansas Adeno-associated virus aav rep78 major regulatory protein, mutants thereof and uses thereof
CA2394980C (en) 1999-12-22 2008-05-13 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US6602498B2 (en) 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
IL152804A0 (en) 2000-05-16 2003-06-24 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
GB0103110D0 (en) 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
US7157596B2 (en) 2000-09-08 2007-01-02 Dendreon Corporation Inhibitors of serine protease activity of matriptase or MTSP1
EP1345628B1 (en) 2000-12-20 2011-04-13 F. Hoffmann-La Roche AG Conjugates of erythropoietin (epo) with polyethylene glycol (peg)
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
WO2002072786A2 (en) 2001-03-13 2002-09-19 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
CA2442089A1 (en) 2001-03-27 2002-10-03 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon
US7112430B2 (en) 2001-05-14 2006-09-26 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
WO2002095007A2 (en) 2001-05-23 2002-11-28 Dendreon San Diego Llc Conjugates activated by cell surface proteases and therapeutic uses thereof
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
EP1436315A2 (en) 2001-10-19 2004-07-14 The Scripps Research Institute Novel methods for introducing molecules into cells and vectors and compositions for use in such methods
EP1446438A2 (en) 2001-11-07 2004-08-18 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7192468B2 (en) 2002-04-15 2007-03-20 Fluor Technologies Corporation Configurations and method for improved gas removal
WO2003104394A2 (en) 2002-05-21 2003-12-18 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembrane serine protease 12, the encoded polypeptides and methods based thereon
US20060024289A1 (en) 2002-10-02 2006-02-02 Ruggles Sandra W Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases
US7939304B2 (en) 2002-10-02 2011-05-10 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
AU2003282724B2 (en) 2002-10-02 2010-03-04 Catalyst Biosciences, Inc. Methods of generating and screening for proteases with altered specificity
KR20040040782A (ko) 2002-11-08 2004-05-13 선바이오(주) 신규한 헥사-암 폴리에틸렌글리콜과 유도체 및 그의합성방법
WO2004058052A2 (en) 2002-12-20 2004-07-15 Applera Corporation Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
US7019019B2 (en) 2002-12-23 2006-03-28 Dendreon Corporation Matriptase inhibitors and methods of use
US20040147027A1 (en) 2003-01-28 2004-07-29 Troy Carol M. Complex for facilitating delivery of dsRNA into a cell and uses thereof
US20060178297A1 (en) 2003-01-28 2006-08-10 Troy Carol M Systems and methods for silencing expression of a gene in a cell and uses thereof
BRPI0407882B1 (pt) 2003-02-26 2021-07-27 Nektar Therapeutics Composição compreendendo conjugados de polímero-porção de fator viii e seu método de fabricação
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
KR100512483B1 (ko) 2003-05-07 2005-09-05 선바이오(주) 신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
EP2644206B1 (en) 2003-05-23 2019-04-03 Nektar Therapeutics PEG derivatives containing two PEG chains
US7595306B2 (en) 2003-06-09 2009-09-29 Alnylam Pharmaceuticals Inc Method of treating neurodegenerative disease
WO2005084158A2 (en) 2003-06-20 2005-09-15 The Regents Of The University Of California Polypeptide transduction and fusogenic peptides
US7439226B2 (en) 2003-09-30 2008-10-21 The United States Of America As Represented By The Department Of Health And Human Services Serine protease inhibitors
PT1718677E (pt) 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
JP5629423B2 (ja) 2004-04-12 2014-11-19 カタリスト バイオサイエンシーズ， インコーポレイテッド 野生型及び変異型ｍｔ−ｓｐ１による、ｖｅｇｆ及びｖｅｇｆ受容体の切断
US8173144B2 (en) 2004-11-04 2012-05-08 L'oreal Administration of urea compounds for combating signs of cutaneous aging
WO2006090389A2 (en) 2005-02-24 2006-08-31 Compugen Ltd. Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
AU2011218753B2 (en) * 2005-10-21 2013-10-24 Vertex Pharmaceuticals Incorporated Modified proteases that inhibit complement activation
JP5219819B2 (ja) 2005-10-21 2013-06-26 カタリスト・バイオサイエンシーズ・インコーポレイテッド 補体活性化を阻害する修飾プロテアーゼ
CA2626868A1 (en) 2005-11-01 2007-05-10 The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizo Na State University Novel protein transduction domains and uses therefor
US7579318B2 (en) 2005-12-06 2009-08-25 Centre De La Recherche De La Scientifique Cell penetrating peptides for intracellular delivery of molecules
KR100859972B1 (ko) 2006-02-20 2008-09-25 이화여자대학교 산학협력단 막투과 단백질 도메인 펩타이드
EP1867661A1 (en) 2006-06-12 2007-12-19 Diatos Compositions and methods for delivering anti-activated ras antibodies into cells
CA2791144C (en) * 2006-07-05 2019-04-09 Catalyst Biosciences, Inc. Protease screening methods and proteases identified thereby
SG175602A1 (en) 2006-07-05 2011-11-28 Catalyst Biosciences Inc Protease screening methods and proteases identified thereby
CA2761310C (en) 2009-05-07 2017-02-28 Charles S. Craik Antibodies and methods of use thereof
CA2843684A1 (en) 2010-08-13 2012-02-16 Tufts University Compositions, kits and methods for treatment of macular degeneration using soluble membrane-independent cd59 protein
US20140329252A1 (en) 2011-10-14 2014-11-06 Hopital Sainte-Justine Methods and kits for diagnosing and/or prognosing osteoarthritis
KR102668696B1 (ko) 2012-01-12 2024-05-29 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US10029415B2 (en) 2012-08-16 2018-07-24 Stratasys, Inc. Print head nozzle for use with additive manufacturing system
WO2014028861A1 (en) * 2012-08-17 2014-02-20 Apellis Pharmaceuticals, Inc. Detection of high risk drusen
CA2836167A1 (en) 2013-12-10 2015-06-10 Christina Xiaolin Dai Thickness increase spring
PL3137595T3 (pl) 2014-04-29 2019-09-30 Novartis Ag Nowe komórki kręgowców i sposoby ekspresji rekombinowanej polipeptydu będącego przedmiotem zainteresowania
WO2016023040A1 (en) 2014-08-08 2016-02-11 Alexo Therapeutics International Sirp-alpha variant constructs and uses thereof
ES2789351T3 (es) 2015-01-13 2020-10-26 Hope City Máscaras de enlace peptídico de proteínas de unión a CTLA4
JP6817962B2 (ja) 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． ターゲティングされたアンドロゲン受容体分解のための化合物および方法
IL296285A (en) 2015-07-06 2022-11-01 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
US11903996B2 (en) * 2015-10-07 2024-02-20 David C. Fritzinger Modulators of complement function
BR112018008918A8 (pt) 2015-11-02 2019-02-26 Univ Yale compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
CA3177086A1 (en) 2017-06-22 2018-12-27 Catalyst Biosciences, Inc. Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use
CA3123872A1 (en) 2018-12-28 2020-07-02 Catalyst Biosciences, Inc. Modified urokinase-type plasminogen activator polypeptides and methods of use

Also Published As

Publication number Publication date
CN111107870A (zh) 2020-05-05
NZ760116A (en) 2024-03-22
JP7773579B2 (ja) 2025-11-19
JOP20190288A1 (ar) 2019-12-16
CA3067851A1 (en) 2018-12-27
SG11201912071QA (en) 2020-01-30
SG10202110500TA (en) 2021-11-29
BR112019027583A2 (pt) 2020-10-06
AU2018290281B2 (en) 2021-12-16
IL308949B2 (en) 2026-03-01
US20200291376A1 (en) 2020-09-17
US10954501B2 (en) 2021-03-23
ZA202000332B (en) 2024-12-18
MY202652A (en) 2024-05-13
AU2022201445B2 (en) 2023-11-23
KR102675270B1 (ko) 2024-06-17
IL271587B2 (en) 2024-05-01
JP2022120155A (ja) 2022-08-17
US11401513B2 (en) 2022-08-02
AU2018290281A1 (en) 2020-01-30
CA3067851C (en) 2023-01-31
US20210355474A1 (en) 2021-11-18
IL271587A (en) 2020-02-27
CA3177086A1 (en) 2018-12-27
IL271587B1 (en) 2024-01-01
US20210032617A1 (en) 2021-02-04
PH12019502838A1 (en) 2020-09-21
EP3641801A1 (en) 2020-04-29
JP2020528742A (ja) 2020-10-01
WO2018237201A1 (en) 2018-12-27
KR20200030063A (ko) 2020-03-19
CL2021003081A1 (es) 2022-08-12
AU2022201445A1 (en) 2022-03-24
US10781435B2 (en) 2020-09-22
PE20200697A1 (es) 2020-06-16
MX2019015402A (es) 2020-07-20
SG10202110492YA (en) 2021-11-29
JP7091373B2 (ja) 2022-06-27
IL308949A (en) 2024-01-01
IL308949B1 (en) 2025-11-01
US12173337B2 (en) 2024-12-24
CL2021003080A1 (es) 2022-08-12
US11807882B2 (en) 2023-11-07
US20240018502A1 (en) 2024-01-18
JP2024095662A (ja) 2024-07-10
CO2020000584A2 (es) 2020-05-05
US20190093097A1 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
CL2019003813A1 (es) Polipéptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y métodos de uso.
ECSP20005581A (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp
CO2019014682A2 (es) Composiciones y métodos para enzimas de internalización
MX381639B (es) Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
MX2023000731A (es) Composiciones utiles para enzimas de internalizacion.
MX2009013332A (es) Inhibidores de ire-1 alfa.
CR20180185A (es) Métodos y composiciones para el tratamiento de estados de enfermedad asociados con respuestas inflamatorias anormales
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
MX2017016655A (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
ECSP18012793A (es) Composición y productos que comprenden células senescentes para su uso en la regeneración de tejidos
BR112015004997A2 (pt) composições contendo misturas de alcanos semifluorados
CL2021001710A1 (es) Polipéptidos de activador de plasminógeno, tipo urocinasa, modificados y métodos de uso
CL2020003447A1 (es) Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas
UY35293A (es) Isotiazoles sustituidos con amino
MX372988B (es) Composiciones oftalmicas estabilizadas de omega 3.
CU20160169A7 (es) Compuestos y composiciones para inducir condrogénesis
EA201992170A1 (ru) Модуляторы экспрессии pcsk9
CO2017002312A2 (es) Compuestos bicíclicos sustituidos
MX2016015635A (es) Metodos y composiciones para evitar la lesion por isquemia-reperfusion en organos.
MX2018013943A (es) Metodo de tratamiento de hiperglucemia.
CO2020000617A2 (es) Novedosos compuestos que activan la ruta nrf2
AR106477A1 (es) Combinación farmacéutica de antagonista del receptor nk3 y biguanidas
CO2020008885A2 (es) Arilsulfatasa a purificada y composiciones de la misma
EA202000017A1 (ru) Модифицированные пептиды сериновой протеазы 1 мембранного типа (mtsp-1) и способы применения
MA42711A1 (fr) Méthodes de traitement d'états pathologiques associés à une activation du complément dépendant de masp-2